Cohort Study of Intraoperative Lung Protective Ventilation Trends in a Large Canadian Health Authority
NCT06821139
COVID, COVID - 19
Surrey, British Columbia, Canada
View Trial DetailsNCT Number: NCT04355624
Novel coronavirus disease (COVID-19) is a newly discovered contagious disease caused by SARS-CoV-2 virus, primarily manifesting as an acute respiratory illness with pneumonia, but can affect multiple organs such as kidney, heart, digestive tract, blood and nervous system. In previous reports of SARS and MERS-CoV infections, acute kidney injury was described in 5 to 15% of patients and was associated with a high mortality rate (60-90%). Recent reports showed renal abnormalities in COVID-9 infected patients. A recent Chinese study also reported that acute kidney injury was an independent risk factor for mortality. However, the exact mechanism of kidney involvement remains unclear: sepsis-related cytokine storm or direct cellular injury from the virus. Also, kidney involvement has not yet been well characterized: heavy albuminuria, hematuria or interstitial nephropathy alone.
A recent study identified viral RNA in kidney tissue and another study succeeded isolating SARS-CoV-2 from the urine sample of an infected patient. These data suggest that the kidney might be a target of this novel coronarivus.
The sponsor suggests characterizing kidney involvement in SARS-CoV-2 infection.
Study objectives are:
* To give an accurate characterization of kidney involvement in COVID-19 * To investigate the physiopathologic mechanism of kidney involvement in SARS-CoV-2 infection * To identify risk factors for kidney involvement in in SARS-CoV-2 infection * To evaluate the impact of kidney involvement in in SARS-CoV-2 infection * To assess the long-term health effect of kidney injury on survivors of in SARS-CoV-2 infection
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Centre hospitalier d'Antibes Juan les pins, Antibes, France
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: until 3 months after discharge or death
Rate of kidney involvement in COVID-19 disease characterized by clinical and biological data
Time frame: until 3 months after discharge or death
biological data and histopathological data if available
Time frame: until 3 months after discharge or death
Rate of death
Time frame: until 3 months after discharge or death
Legnth of hopital stay
Time frame: until 3 months after discharge
Recovery of Kidney fonction
Centre Hospitalier Universitaire de Nice
Other
Characterization of Kidney Involvement in COVID-19 Disease: a French Multi-center Prospective Observational Study
Acronym: COVKID
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06821139
COVID, COVID - 19
Surrey, British Columbia, Canada
View Trial DetailsNCT03590327
Apathy, COVID
Little Rock, Arkansas, United States
View Trial DetailsNCT04447833
ARDS, Human, COVID
Uppsala, Sweden
View Trial DetailsNCT04367545
COVID, RT-ddPCR Multiplex
Rouen, France
View Trial Details